Resmetirom in the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis
Life · 18.08.2025 · 15 (8) · 1306
DOI: 10.3390/life15081306 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Life, online erschienen am 18.08.2025. Verfasst von Fares Jamal und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Oncology, Mayo Clinic, Phoenix, AZ 85259, USA. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction-associated steatohepatitis (MASH), are among the most prevalent causes of chronic liver disease worldwide, closely linked to the global rise in overweight and obesity, type 2 diabetes, and metabolic syndrome. Until recently, treatment options were limited to lifestyle interventions, with no approved pharmacologic therapies. Resmetirom, a liver-directed, selective thyroid hormone receptor beta (THR-β) agonist, is a promising disease-modifying agent that targets hepatic lipid metabolism, inflammation, and fibrosis. Clinical trials, including the pivotal phase 3 MAESTRO-NASH and MAESTRO-NAFLD-1 trials, have demonstrated significant improvements in liver fat reduction, lipid profiles, histological endpoints, and health-related quality of life, with a favorable safety profile. In March 2024, the FDA granted accelerated approval of resmetirom for adults with MASH and moderate-to-advanced fibrosis, marking a significant milestone in MASLD treatment. This review discusses the mechanistic rationale, preclinical data, and pivotal clinical trial outcomes supporting resmetirom’s role in MASLD/MASH management, while outlining ongoing research needs, including long-term safety, pediatric evaluation, and biomarker development for optimized patient selection.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology and Oncology, Mayo Clinic, Phoenix, AZ 85259, USA.
- Department of Gastroenterology and Hepatology, Mayo Clinic, Phoenix, AZ 85259, USA.
- Department of Cardiovascular Medicine and Surgery, Mayo Clinic, Phoenix, AZ 85054, USA.
- Department of Colorectal Surgery, Mayo Clinic, Phoenix, AZ 85054, USA.
- Department of Medicine, Mayo Clinic, Phoenix, AZ 85054, USA.
- Department of Medicine, Indiana University, Indianapolis, IN 46202, USA.
ORCID-Profile: Fares Jamal, Hashem N Albunni, Channa R Jayasekera, Bashar A Aqel
Zitieren
APA
Jamal, F., Elshaer, A., Odeh, N. B., Alatout, M. H., Shahin, T., Worden, A. R., Albunni, H. N., Lizaola-Mayo, B. C., Jayasekera, C. R., Chascsa, D. M. H., Vargas, H. E., & Aqel, B. A. (2025). Resmetirom in the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis. Life, 15(8), 1306. https://doi.org/10.3390/life15081306
Vancouver
Jamal F, Elshaer A, Odeh NB, Alatout MH, Shahin T, Worden AR, et al. Resmetirom in the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis. Life. 2025;15(8):1306. doi:10.3390/life15081306
BibTeX
@article{Jamal2025,
author = {Jamal, Fares and Elshaer, Amani and Odeh, Nour B and Alatout, Mayar H and Shahin, Tala and Worden, Astin R and Albunni, Hashem N and Lizaola-Mayo, Blanca C and Jayasekera, Channa R and Chascsa, David M H and Vargas, Hugo E and Aqel, Bashar A},
title = {Resmetirom in the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis},
journal = {Life},
year = {2025},
volume = {15},
number = {8},
pages = {1306},
doi = {10.3390/life15081306}
}
EUVIMED